Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Minerva Neurosciences, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
NERV
Nasdaq
2830
www.minervaneurosciences.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Minerva Neurosciences, Inc.
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
- Nov 19th, 2025 6:30 am
Minerva Neurosciences: Q3 Earnings Snapshot
- Nov 5th, 2025 5:40 am
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
- Nov 5th, 2025 5:30 am
Top Midday Gainers
- Oct 21st, 2025 11:36 am
BC-Most Active Stocks
- Oct 21st, 2025 8:30 am
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
- Oct 21st, 2025 6:00 am
Minerva Neurosciences: Q2 Earnings Snapshot
- Aug 14th, 2025 2:43 pm
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
- Aug 14th, 2025 2:35 pm
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
- May 13th, 2025 5:30 am
Minerva Neurosciences: Q1 Earnings Snapshot
- May 13th, 2025 5:22 am
Minerva Neurosciences: Q4 Earnings Snapshot
- Feb 25th, 2025 5:32 am
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
- Feb 25th, 2025 5:00 am
Scroll